IBDEI0J2 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8948,2)
 ;;=^18161
 ;;^UTILITY(U,$J,358.3,8949,0)
 ;;=275.2^^38^504^3
 ;;^UTILITY(U,$J,358.3,8949,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8949,1,4,0)
 ;;=4^METABOLISM D/O,MAGNESIUM
 ;;^UTILITY(U,$J,358.3,8949,1,5,0)
 ;;=5^275.2
 ;;^UTILITY(U,$J,358.3,8949,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,8950,0)
 ;;=275.3^^38^504^5
 ;;^UTILITY(U,$J,358.3,8950,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8950,1,4,0)
 ;;=4^METABOLISM D/O,PHOSPHORUS
 ;;^UTILITY(U,$J,358.3,8950,1,5,0)
 ;;=5^275.3
 ;;^UTILITY(U,$J,358.3,8950,2)
 ;;=^93796
 ;;^UTILITY(U,$J,358.3,8951,0)
 ;;=275.9^^38^504^4
 ;;^UTILITY(U,$J,358.3,8951,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8951,1,4,0)
 ;;=4^METABOLISM D/O,MINERAL
 ;;^UTILITY(U,$J,358.3,8951,1,5,0)
 ;;=5^275.9
 ;;^UTILITY(U,$J,358.3,8951,2)
 ;;=^267943
 ;;^UTILITY(U,$J,358.3,8952,0)
 ;;=588.0^^38^504^13
 ;;^UTILITY(U,$J,358.3,8952,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8952,1,4,0)
 ;;=4^RENAL OSTEODYSTROPHY
 ;;^UTILITY(U,$J,358.3,8952,1,5,0)
 ;;=5^588.0
 ;;^UTILITY(U,$J,358.3,8952,2)
 ;;=^104747
 ;;^UTILITY(U,$J,358.3,8953,0)
 ;;=268.9^^38^504^14
 ;;^UTILITY(U,$J,358.3,8953,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8953,1,4,0)
 ;;=4^VITAMIN D DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,8953,1,5,0)
 ;;=5^268.9
 ;;^UTILITY(U,$J,358.3,8953,2)
 ;;=^126968
 ;;^UTILITY(U,$J,358.3,8954,0)
 ;;=251.2^^38^505^15
 ;;^UTILITY(U,$J,358.3,8954,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8954,1,4,0)
 ;;=4^HYPOGLYCEMIA NOS
 ;;^UTILITY(U,$J,358.3,8954,1,5,0)
 ;;=5^251.2
 ;;^UTILITY(U,$J,358.3,8954,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,8955,0)
 ;;=250.01^^38^505^7
 ;;^UTILITY(U,$J,358.3,8955,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8955,1,4,0)
 ;;=4^DMI w/o COMPLICATIONS
 ;;^UTILITY(U,$J,358.3,8955,1,5,0)
 ;;=5^250.01
 ;;^UTILITY(U,$J,358.3,8955,2)
 ;;=^331780
 ;;^UTILITY(U,$J,358.3,8956,0)
 ;;=250.11^^38^505^3
 ;;^UTILITY(U,$J,358.3,8956,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8956,1,4,0)
 ;;=4^DMI w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,8956,1,5,0)
 ;;=5^250.11
 ;;^UTILITY(U,$J,358.3,8956,2)
 ;;=^331784
 ;;^UTILITY(U,$J,358.3,8957,0)
 ;;=250.21^^38^505^2
 ;;^UTILITY(U,$J,358.3,8957,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8957,1,4,0)
 ;;=4^DMI w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,8957,1,5,0)
 ;;=5^250.21
 ;;^UTILITY(U,$J,358.3,8957,2)
 ;;=^331788
 ;;^UTILITY(U,$J,358.3,8958,0)
 ;;=250.41^^38^505^5
 ;;^UTILITY(U,$J,358.3,8958,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8958,1,4,0)
 ;;=4^DMI w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,8958,1,5,0)
 ;;=5^250.41
 ;;^UTILITY(U,$J,358.3,8958,2)
 ;;=^331796
 ;;^UTILITY(U,$J,358.3,8959,0)
 ;;=250.51^^38^505^1
 ;;^UTILITY(U,$J,358.3,8959,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8959,1,4,0)
 ;;=4^DMI w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,8959,1,5,0)
 ;;=5^250.51
 ;;^UTILITY(U,$J,358.3,8959,2)
 ;;=^331800
 ;;^UTILITY(U,$J,358.3,8960,0)
 ;;=250.61^^38^505^4
 ;;^UTILITY(U,$J,358.3,8960,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8960,1,4,0)
 ;;=4^DMI w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,8960,1,5,0)
 ;;=5^250.61
 ;;^UTILITY(U,$J,358.3,8960,2)
 ;;=^331804
 ;;^UTILITY(U,$J,358.3,8961,0)
 ;;=250.71^^38^505^6
 ;;^UTILITY(U,$J,358.3,8961,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8961,1,4,0)
 ;;=4^DMI w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,8961,1,5,0)
 ;;=5^250.71
 ;;^UTILITY(U,$J,358.3,8961,2)
 ;;=^331808
 ;;^UTILITY(U,$J,358.3,8962,0)
 ;;=250.00^^38^505^14
 ;;^UTILITY(U,$J,358.3,8962,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8962,1,4,0)
 ;;=4^DMII w/o COMPLICATIONS
 ;;^UTILITY(U,$J,358.3,8962,1,5,0)
 ;;=5^250.00
 ;;
 ;;$END ROU IBDEI0J2
